Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;9(3):e003071.
doi: 10.1136/rmdopen-2023-003071.

Microvascular damage in autoimmune connective tissue diseases: a capillaroscopic analysis from 20 years of experience in a EULAR training and research referral centre for imaging

Affiliations

Microvascular damage in autoimmune connective tissue diseases: a capillaroscopic analysis from 20 years of experience in a EULAR training and research referral centre for imaging

Elvis Hysa et al. RMD Open. 2023 Jul.

Abstract

Objective: Nailfold videocapillaroscopy (NVC) allows the detection of microvascular damage in autoimmune connective tissue diseases (CTDs). The prevalence of the morphological capillary findings was retrospectively evaluated in a wide cohort of patients with Raynaud's phenomenon secondary to a CTD at the time of the first single NVC, independently from their current treatment, autoantibody profile and comorbidities.

Methods: One-thousand-one-hundred-eighty-one patients affected by CTDs were included from 2001 to 2021. The considered CTDs were systemic sclerosis (SSc), undifferentiated connective tissue disease (UCTD), mixed connective tissue disease (MCTD), dermatomyositis (DM), systemic lupus erythematosus, Sjögren's syndrome and primary antiphospholipid syndrome (aPS). The capillaroscopic parameters were distinguished between scleroderma patterns and non-scleroderma patterns.

Results: Giant capillaries were significantly more frequent in SSc, DM and MCTD than in other CTDs (respectively, in 73%, 73% and 61% of patients, p<0.001 when comparing each rate vs the other CTDs). The mean capillary count was significantly lower in SSc, DM and MCTD (respectively, 7.04±0.18 vs 6.5±0.75 vs 7.7±2 capillaries/linear mm) compared with the other CTDs (p<0.001 for each rate vs the other CTDs). The non-specific abnormalities of capillary morphology were significantly more frequent in SSc, MCTD and aPS (respectively, in 48%, 41% and 36% of cases, all p<0.001 vs each other CTDs).

Conclusion: This large size sample of patients with CTDs, collected over 20 years of analysis, confirms the highest prevalence of specific capillaroscopic alterations in patients with SSc, DM and MCTD, when compared with other CTDs.

Keywords: Sjogren's syndrome; antiphospholipid syndrome; dermatomyositis; lupus erythematosus, systemic; scleroderma, systemic.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Microvascular morphological alterations detectable on NVC in autoimmune CTDs. (A) Giant capillaries in an SSc patient with an ‘active’ scleroderma pattern. (B) Scleroderma-like pattern in a patient with MCTD. (C) ‘Comb-like’ microhaemorrhages in a patient with primary aPS. aPS, antiphospholipid syndrome; CTDs, connective tissue diseases; MCTD, mixed connective tissue disease; NVC, nailfold videocapillaroscopy; SSc, systemic sclerosis.
Figure 2
Figure 2
Mean capillary density, rates of giant capillaries, abnormally shaped capillaries and microhaemorrhages in CTDs. aPS, antiphospholipid syndrome; CTDs, connective tissue diseases; DM, dermatomyositis; MCTD, mixed connective tissue disease; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc, systemic sclerosis; UCTD, undifferentiated connective tissue disease.

Similar articles

Cited by

References

    1. Suter LG, Murabito JM, Felson DT, et al. . The incidence and natural history of Raynaud’s phenomenon in the community. Arthritis Rheum 2005;52:1259–63. 10.1002/art.20988 - DOI - PubMed
    1. García-Carrasco M, Sisó A, Ramos-Casals M, et al. . Raynaud’s phenomenon in primary Sjögren’s syndrome. prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 2002;29:726–30. - PubMed
    1. Heimovski FE, Simioni JA, Skare TL. Systemic lupus erythematosus and Raynaud's phenomenon. An Bras Dermatol 2015;90:837–40. 10.1590/abd1806-4841.20153881 - DOI - PMC - PubMed
    1. Ingegnoli F, Ughi N, Dinsdale G, et al. . An international survey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with Raynaud’s phEnomenon (SUNSHINE survey). Rheumatol Int 2017;37:1879–90. 10.1007/s00296-017-3808-0 - DOI - PubMed
    1. LeRoy EC, Medsger TA. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485–8. - PubMed

MeSH terms